Argatroban warnings and precautions: Difference between revisions

Revision as of 01:57, 4 March 2014

Argatroban
Argatroban^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]

Adapted from the FDA Package Insert.

Revision as of 23:17, 3 March 2014 (view source) Jesus Hernandez (talk \| contribs) (Created page with "__NOTOC__ {{Argatroban}} {{CMG}}; {{AE}} {{JH}} ==TITLE== <ref name="dailymed.nlm.nih.gov">{{Cite web \| last = \| first = \| title = ARGATROBAN INJECTION, SOLUTION [GLAXO...")		Revision as of 01:57, 4 March 2014 (view source) Jesus Hernandez (talk \| contribs) No edit summary Newer edit →
Line 3:		Line 3:
	{{CMG}}; {{AE}} {{JH}}		{{CMG}}; {{AE}} {{JH}}

	==~~TITLE~~==		==Warnings and Precautions==